Cargando…
Constructing germline research cohorts from the discarded reads of clinical tumor sequences
BACKGROUND: Hundreds of thousands of cancer patients have had targeted (panel) tumor sequencing to identify clinically meaningful mutations. In addition to improving patient outcomes, this activity has led to significant discoveries in basic and translational domains. However, the targeted nature of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576948/ https://www.ncbi.nlm.nih.gov/pubmed/34749793 http://dx.doi.org/10.1186/s13073-021-00999-4 |
_version_ | 1784595980700614656 |
---|---|
author | Gusev, Alexander Groha, Stefan Taraszka, Kodi Semenov, Yevgeniy R. Zaitlen, Noah |
author_facet | Gusev, Alexander Groha, Stefan Taraszka, Kodi Semenov, Yevgeniy R. Zaitlen, Noah |
author_sort | Gusev, Alexander |
collection | PubMed |
description | BACKGROUND: Hundreds of thousands of cancer patients have had targeted (panel) tumor sequencing to identify clinically meaningful mutations. In addition to improving patient outcomes, this activity has led to significant discoveries in basic and translational domains. However, the targeted nature of clinical tumor sequencing has a limited scope, especially for germline genetics. In this work, we assess the utility of discarded, off-target reads from tumor-only panel sequencing for the recovery of genome-wide germline genotypes through imputation. METHODS: We developed a framework for inference of germline variants from tumor panel sequencing, including imputation, quality control, inference of genetic ancestry, germline polygenic risk scores, and HLA alleles. We benchmarked our framework on 833 individuals with tumor sequencing and matched germline SNP array data. We then applied our approach to a prospectively collected panel sequencing cohort of 25,889 tumors. RESULTS: We demonstrate high to moderate accuracy of each inferred feature relative to direct germline SNP array genotyping: individual common variants were imputed with a mean accuracy (correlation) of 0.86, genetic ancestry was inferred with a correlation of > 0.98, polygenic risk scores were inferred with a correlation of > 0.90, and individual HLA alleles were inferred with a correlation of > 0.80. We demonstrate a minimal influence on the accuracy of somatic copy number alterations and other tumor features. We showcase the feasibility and utility of our framework by analyzing 25,889 tumors and identifying the relationships between genetic ancestry, polygenic risk, and tumor characteristics that could not be studied with conventional on-target tumor data. CONCLUSIONS: We conclude that targeted tumor sequencing can be leveraged to build rich germline research cohorts from existing data and make our analysis pipeline publicly available to facilitate this effort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00999-4. |
format | Online Article Text |
id | pubmed-8576948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85769482021-11-10 Constructing germline research cohorts from the discarded reads of clinical tumor sequences Gusev, Alexander Groha, Stefan Taraszka, Kodi Semenov, Yevgeniy R. Zaitlen, Noah Genome Med Research BACKGROUND: Hundreds of thousands of cancer patients have had targeted (panel) tumor sequencing to identify clinically meaningful mutations. In addition to improving patient outcomes, this activity has led to significant discoveries in basic and translational domains. However, the targeted nature of clinical tumor sequencing has a limited scope, especially for germline genetics. In this work, we assess the utility of discarded, off-target reads from tumor-only panel sequencing for the recovery of genome-wide germline genotypes through imputation. METHODS: We developed a framework for inference of germline variants from tumor panel sequencing, including imputation, quality control, inference of genetic ancestry, germline polygenic risk scores, and HLA alleles. We benchmarked our framework on 833 individuals with tumor sequencing and matched germline SNP array data. We then applied our approach to a prospectively collected panel sequencing cohort of 25,889 tumors. RESULTS: We demonstrate high to moderate accuracy of each inferred feature relative to direct germline SNP array genotyping: individual common variants were imputed with a mean accuracy (correlation) of 0.86, genetic ancestry was inferred with a correlation of > 0.98, polygenic risk scores were inferred with a correlation of > 0.90, and individual HLA alleles were inferred with a correlation of > 0.80. We demonstrate a minimal influence on the accuracy of somatic copy number alterations and other tumor features. We showcase the feasibility and utility of our framework by analyzing 25,889 tumors and identifying the relationships between genetic ancestry, polygenic risk, and tumor characteristics that could not be studied with conventional on-target tumor data. CONCLUSIONS: We conclude that targeted tumor sequencing can be leveraged to build rich germline research cohorts from existing data and make our analysis pipeline publicly available to facilitate this effort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00999-4. BioMed Central 2021-11-08 /pmc/articles/PMC8576948/ /pubmed/34749793 http://dx.doi.org/10.1186/s13073-021-00999-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gusev, Alexander Groha, Stefan Taraszka, Kodi Semenov, Yevgeniy R. Zaitlen, Noah Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title | Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title_full | Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title_fullStr | Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title_full_unstemmed | Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title_short | Constructing germline research cohorts from the discarded reads of clinical tumor sequences |
title_sort | constructing germline research cohorts from the discarded reads of clinical tumor sequences |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576948/ https://www.ncbi.nlm.nih.gov/pubmed/34749793 http://dx.doi.org/10.1186/s13073-021-00999-4 |
work_keys_str_mv | AT gusevalexander constructinggermlineresearchcohortsfromthediscardedreadsofclinicaltumorsequences AT grohastefan constructinggermlineresearchcohortsfromthediscardedreadsofclinicaltumorsequences AT taraszkakodi constructinggermlineresearchcohortsfromthediscardedreadsofclinicaltumorsequences AT semenovyevgeniyr constructinggermlineresearchcohortsfromthediscardedreadsofclinicaltumorsequences AT zaitlennoah constructinggermlineresearchcohortsfromthediscardedreadsofclinicaltumorsequences |